Literature DB >> 20680520

The effect of human umbilical cord blood cells on survival and cytokine production by post-ischemic astrocytes in vitro.

Lixian Jiang1, Samuel Saporta, Ning Chen, Cyndy Davis Sanberg, Paul Sanberg, Alison Willing.   

Abstract

Cerebral ischemia induces death of all neural cell types within the region affected by the loss of blood flow. We have shown that administering human umbilical cord blood cells after a middle cerebral artery occlusion in rats significantly reduces infarct size, presumably by rescuing cells within the penumbra. In this study we examined whether the cord blood cells enhanced astrocyte survival in an in vitro model of hypoxia with reduced glucose availability. Primary astrocyte cultures were incubated for 2 h in no oxygen (95% N, 5% CO(2)) and low glucose (1% compared to 4.5%) media. Cord blood mononuclear cells were added to half the cultures at the beginning of hypoxia. Astrocyte viability was determined using fluorescein diacetate/propidium iodide (FDA/PI) labeling and cytokine production by the astrocytes measured using ELISA. In some studies, T cells, B cells or monocytes/macrophages isolated from the cord blood mononuclear fraction with magnetic antibody cell sorting (MACS) were used instead to determine which cellular component of the cord blood mononuclear fraction was responsible for the observed effects. Co-culturing mononuclear cord blood cells with astrocytes during hypoxia stimulated production of IL-6 and IL-10 during hypoxia. The cord blood T cells decreased survival of the astrocytes after hypoxia but had no effect on the examined cytokines. Our data demonstrate that the tested cord blood fractions do not enhance astrocyte survival when delivered individually, suggesting there is either another cellular component that is neuroprotective or an interaction of all the cells is essential for protection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20680520     DOI: 10.1007/s12015-010-9174-x

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  9 in total

1.  Interleukin (IL)-1beta-mediated apoptosis of human astrocytes.

Authors:  L C Ehrlich; P K Peterson; S Hu
Journal:  Neuroreport       Date:  1999-06-23       Impact factor: 1.837

2.  Human umbilical cord blood cells express neurotrophic factors.

Authors:  Cun-Gang Fan; Qing-Jun Zhang; Feng-Wu Tang; Zhi-Bo Han; Ge-Sheng Wang; Zhong-Chao Han
Journal:  Neurosci Lett       Date:  2005-02-12       Impact factor: 3.046

3.  Timing of cord blood treatment after experimental stroke determines therapeutic efficacy.

Authors:  Jennifer D Newcomb; Craig T Ajmo; Cyndy D Sanberg; Paul R Sanberg; Keith R Pennypacker; Alison E Willing
Journal:  Cell Transplant       Date:  2006       Impact factor: 4.064

4.  Activation-induced cell death of rat astrocytes.

Authors:  K Suk; J Lee; J Hur; Y S Kim; M Lee; S Cha; S Yeou Kim; H Kim
Journal:  Brain Res       Date:  2001-05-11       Impact factor: 3.252

5.  Human umbilical cord blood cells decrease microglial survival in vitro.

Authors:  Lixian Jiang; Tracy Womble; Samuel Saporta; Ning Chen; Cyndy Davis Sanberg; Paul R Sanberg; Alison E Willing
Journal:  Stem Cells Dev       Date:  2010-02       Impact factor: 3.272

6.  Umbilical cord blood stem cells can expand hematopoietic and neuroglial progenitors in vitro.

Authors:  Colin P McGuckin; Nicolas Forraz; Quentin Allouard; Ruth Pettengell
Journal:  Exp Cell Res       Date:  2004-05-01       Impact factor: 3.905

7.  Umbilical cord blood mesenchymal stromal cells are neuroprotective and promote regeneration in a rat optic tract model.

Authors:  Isabel Zwart; Andrew J Hill; Faisal Al-Allaf; Mili Shah; John Girdlestone; Athirah B R Sanusi; Huseyin Mehmet; Roberto Navarrete; Cristina Navarrete; Ling-Sun Jen
Journal:  Exp Neurol       Date:  2009-04       Impact factor: 5.330

8.  Proliferation, differentiation, and cytokine secretion of human umbilical cord blood-derived mononuclear cells in vitro.

Authors:  Sandra Neuhoff; Janet Moers; Maike Rieks; Thomas Grunwald; Arne Jensen; Rolf Dermietzel; Carola Meier
Journal:  Exp Hematol       Date:  2007-07       Impact factor: 3.084

9.  Evidence for neuroprotective properties of human umbilical cord blood cells after neuronal hypoxia in vitro.

Authors:  Susann Hau; Doreen M Reich; Markus Scholz; Wilfried Naumann; Frank Emmrich; Manja Kamprad; Johannes Boltze
Journal:  BMC Neurosci       Date:  2008-02-29       Impact factor: 3.288

  9 in total
  5 in total

1.  Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-β-associated neuropathology in Alzheimer mice.

Authors:  Donna Darlington; Juan Deng; Brian Giunta; Huayan Hou; Cyndy D Sanberg; Nicole Kuzmin-Nichols; Hua-Dong Zhou; Takashi Mori; Jared Ehrhart; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2012-09-05       Impact factor: 3.272

Review 2.  Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options.

Authors:  Courtney A McDonald; Michael C Fahey; Graham Jenkin; Suzanne L Miller
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

Review 3.  Brain-immune interactions in perinatal hypoxic-ischemic brain injury.

Authors:  Bo Li; Katherine Concepcion; Xianmei Meng; Lubo Zhang
Journal:  Prog Neurobiol       Date:  2017-10-27       Impact factor: 11.685

4.  17-DMAG diminishes hemorrhage-induced small intestine injury by elevating Bcl-2 protein and inhibiting iNOS pathway, TNF-α increase, and caspase-3 activation.

Authors:  Juliann G Kiang; Neil G Agravante; Joan T Smith; Phillip D Bowman
Journal:  Cell Biosci       Date:  2011-06-03       Impact factor: 7.133

5.  Human umbilical cord blood monocytes, but not adult blood monocytes, rescue brain cells from hypoxic-ischemic injury: Mechanistic and therapeutic implications.

Authors:  Arjun Saha; Sachit Patel; Li Xu; Paula Scotland; Jonathan Schwartzman; Anthony J Filiano; Joanne Kurtzberg; Andrew E Balber
Journal:  PLoS One       Date:  2019-09-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.